EXO Biologics

Executive Summary

EXO Biologics is a Belgian biotechnology company founded in 2015 that specializes in developing next-generation nanomedicines based on extracellular vesicles (EVs) and exosomes. The company's platform focuses on leveraging exosomes as natural therapeutic messengers and drug delivery vehicles to address rare inflammatory diseases with high unmet medical needs. EXO Biologics has established a state-of-the-art GMP manufacturing facility and a proprietary drug loading platform, positioning itself as an integrated player in the exosome therapeutics space. The company's strategy encompasses both therapeutic development and platform commercialization, aiming to provide novel treatment options for patients with limited alternatives. With an approved status (likely referring to regulatory approval of its manufacturing or platform), EXO Biologics is poised to advance its lead programs toward clinical validation and potential partnerships. The company is private and headquartered in Gosselies, Belgium.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 Trial for Lead Candidate in Rare Inflammatory Disease60% success
• Q4 2026Strategic Partnership for Manufacturing or Co-Development50% success
• Q2 2026FDA Orphan Drug Designation for Lead Program70% success